Repare Therapeutics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RPTX research report →
Range $3 – $30
Price Chart
About the company
Repare Therapeutics Inc. is a precision oncology biopharmaceutical company in the clinical stage, focused on discovering and developing innovative therapies. Operating across Canada and the United States, the company leverages a synthetic lethality approach to identify new treatments.
- CEO
- Steve Forte
- IPO
- 2020
- Employees
- 129
- HQ
- Montreal, QC, CA
Get TickerSpark's AI analysis on RPTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $114.24M
- P/E
- -2.59
- PEG
- 0.10
- P/S
- 9.62
- P/B
- 0.99
- EV/EBITDA
- -0.87
- Div Yield
- 0.00%
- Gross Margin
- 26.81%
- Op Margin
- -374.36%
- Net Margin
- -366.71%
- ROE
- -37.24%
- ROIC
- -38.48%
Latest fiscal year · YoY change
- Revenue
- $53.48M+4.6%
- Gross Profit
- $40.10M+5.8%
- Op Income
- $-93,523,000
- Net Income
- $-84,689,000+9.7%
- EPS
- $-2.00+10.3%
- OCF Growth
- +39.9%
- FCF Growth
- +40.8%
- 52W High
- $2.66
- 52W Low
- $0.89
- 50D MA
- $2.35
- 200D MA
- $1.75
- Beta
- 0.96
- Avg Volume
- 1.18M
No earnings-call transcripts are available for RPTX yet.
- Free Float
- 80.4%
- Shares Outstanding
- 43.11M
- Float Shares
- 34.66M
of shares held by institutions
45 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Aquilo Capital Management, LLC | 1.29M | 0 |
| Mpm Asset Management LLC | 1.12M | 0 |
| Militia Capital Partners, LP | 119.18K | 0 |
| Two Sigma Advisers, LP | 54.20K | ▲ 26.50K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 28, 26 | BVF PARTNERS L P/IL | other | 548,938 |
| Jan 28, 26 | SCHAFER CAROL | sell | 37,941 |
| Jan 28, 26 | SCHAFER CAROL | sell | 8,000 |
| Jan 28, 26 | RHOADS ANN D | sell | 4,000 |
| Jan 28, 26 | Civik Thomas | sell | 7,500 |
| Jan 28, 26 | Forte Steve | sell | 325,800 |
| Jan 28, 26 | Forte Steve | sell | 85,000 |
| Jan 28, 26 | Forte Steve | sell | 56,786 |
| Jan 28, 26 | Forte Steve | sell | 500,000 |
| Jan 28, 26 | Alves Sandra Isabelle Barros | sell | 26,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our RPTX coverage
Recent articles, reports, and earnings notes.
No research on RPTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RPTX report →Repare Therapeutics (NASDAQ:RPTX) Trading Up 0.8% – What’s Next?
defenseworld.net · Feb 20
Repare Shareholders Approve Acquisition by XenoTherapeutics, Inc.
businesswire.com · Jan 16
Repare Therapeutics (NASDAQ:RPTX) Stock Price Up 0.4% – Here’s Why
defenseworld.net · Jan 15
Repare Therapeutics Target of Unusually Large Options Trading (NASDAQ:RPTX)
defenseworld.net · Dec 25
Repare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration
businesswire.com · Dec 24
Halper Sadeh LLC Encourages UBFO, CWBC, RPTX Shareholders to Contact the Firm to Discuss Their Rights
prnewswire.com · Dec 18
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Repare Therapeutics Inc. (Nasdaq – RPTX), Axalta Coating Systems Ltd. (NYSE – AXTA), Blue Foundry Bancorp (Nasdaq – BLFY), Golden Entertainment, Inc (Nasdaq - GDEN)
globenewswire.com · Dec 8
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger—RPTX, CNBN, KMB, and KVUE
globenewswire.com · Dec 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.